Home › Allied-Bristol Life Sciences Launches ieCa Therapeutics From NYU School Of Medicine To Develop Novel Cancer Therapeutics Targeting The Wnt Pathway
 

Keywords :   


Allied-Bristol Life Sciences Launches ieCa Therapeutics From NYU School Of Medicine To Develop Novel Cancer Therapeutics Targeting The Wnt Pathway

2016-03-30 07:03:23| drugdiscoveryonline Home Page

Allied-Bristol Life Sciences, LLC (ABLS), a biopharmaceutical enterprise jointly owned between Allied Minds and Bristol-Myers Squibb Company, announced that it has launched a new subsidiary, iβeCa Therapeutics, to license proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway

Tags: the life school develop

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »